Cellectar Biosciences, Inc.
CLRBDrugs in Pipeline
4
Phase 3 Programs
2
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
Iopofosine I 131 single dose Phase 2 Results Expected
Primary completion for Iopofosine I 131 single dose trial (NCT02952508) in Waldenstrom Macroglobulinemia
83.6% ORR and 61.8% MRR achieved with median duration of response of 17.8 months in heavily pretreated population
SourcePaclitaxel
Non Small Cell Lung Cancer
NOV-002
Ovarian Cancer
NOV-205
Hepatitis C
Iopofosine I 131 single dose
Waldenstrom Macroglobulinemia
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Paclitaxel | Phase 3 | Non Small Cell Lung Cancer | - | Patent 2034 |
NOV-002 | Phase 3 | Ovarian Cancer | - | - |
NOV-205 | Phase 2 | Hepatitis C | - | - |
Iopofosine I 131 single dose | Phase 2 | Waldenstrom Macroglobulinemia | - | - |
Non Small Cell Lung Cancer
1 drug in this indication
Waldenstrom Macroglobulinemia
1 drug in this indication
Hepatitis C
1 drug in this indication
Ovarian Cancer
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)